Most Would Fail to Benefit From JUPITER Intervention  by Plonk, William M.
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August 18, 2009:743–6eturn to the community and will require care from subspecialists
ith expertise in their management. The certified advanced heart
ailure and transplant cardiologist will have recognized expertise in
he full range of treatment options available to the patient with
dvanced heart failure and be fully qualified to care for patients
eceiving these treatments as they return to the community. We
elieve that recipients of certification in advanced heart failure and
ransplant cardiology, having demonstrated their competencies in
ll aspects of advanced heart failure management, will provide a
ital function both in the advanced heart failure center and within
he health care community at large.
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ost Would Fail to Benefit
rom JUPITER Intervention
he recent article by Michos and Blumenthal (1) estimates that
.5 million Americans are newly appropriate for statin therapy
ased on JUPITER (Justification for the Use of Statins in
rimary Prevention: an Intervention Trial Evaluating Rosuvas-
atin) study data. The authors fail to recognize, however, that
ost of these patients will die before they are likely to benefit.
As JUPITER reported an annual control event rate of 1.36%
or its primary end point, it would take 50.6 years for one-half
f the study population to benefit from the intervention. From
his value and published National Center for Health Statistics
ife expectancies, one can calculate from Table 1 the proportion
ikely to benefit at any given age.
Risk reduction is not beneficial if it does not prevent an
dverse outcome. Subjecting aging patients to an intervention
roportion Likely to Benefit FromUPITER Interventi n by Sex and Age
Table 1
Proportion Likely to Benefit From
JUPITER Intervention by Sex and Age
Age, Yrs
50 60 70 80 90
Men (%) 32 24 17 10 5trom which the overwhelming majority will not benefit is
linically inappropriate.
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eply
e thank Dr. Plonk for his letter regarding our recent publication
1). We agree that the incident rates for the primary end point in
he JUPITER (Justification for the Use of Statins in Primary
revention: an Intervention Trial Evaluating Rosuvastatin) trial
ere overall moderate in this primary prevention trial (0.77 and
.36 per 100 person-years of follow-up in the rosuvastatin and
lacebo groups, respectively) (2).
If we are interpreting Dr. Plonk’s analyses correctly, he applied
he 1.36% annual event rate found in the JUPITER placebo group
qually across age groups in his table, only accounting for de-
reased life expectancy with age. However, the risk of cardiovas-
ular events, many of which are nonfatal, also increases signifi-
antly with age (3). It appears that Dr. Plonk did not account for
he increasing risk for the events with age when he stratified by age
roups. Therefore, although the life expectancy is shorter at older
ges, the risk of cardiovascular events is greater, which means the
roportion that may benefit in the older age groups is likely greater
han his table suggests.
The median age in the JUPITER clinical trial was 66 years, and
he weighted median age group found in our NHANES (National
ealth and Nutrition Examination Survey) participants represen-
ative of the general U.S. population who met JUPITER eligibility
as similar at 67 years (interquartile range 57 to 75 years; median
ge of 60 years for men and 74 years for women). Therefore, even
hen Dr. Plonk’s estimates are used, a significant portion (20%
o 25%) of eligible 55- to 75-year-old patients would likely benefit
sing this JUPITER strategy.
Furthermore, in JUPITER trial, there are 5,500 patients 70
ears of age, and that subgroup had a highly significant 40%
eduction in the trial primary end point (95% confidence interval:
.45 to 0.82) with about a 2-year average follow-up time (Dr. Paul
. Ridker, personal communication, April 8, 2009). The purpose
f our analyses was simply to estimate the number of U.S. adults
ho would meet the JUPITER eligibility criteria. By increasing
ecades of age (50 to 59 years, 60 to 69 years, 70 to 79 years, 80
o 89 years), we estimate by using NHANES data that 29.4%,
7.8%, 28.1%, and 14.7% respectively, would meet JUPITER
ligibility criteria. Certainly the decision whether to initiate statin
herapy should be made on a patient-specific basis, and statinWomen (%) 36 28 19 12 6
herapy may not be indicated in those patients who are unlikely to
